A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.

Kalunian KC; Furie R; Morand EF; Bruce IN; Manzi S; Tanaka Y; Winthrop K; Hupka I; Zhang LJ; Werther S

doi:10.1002/art.42392

A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.

Identifier:nobleid.org/w1/20260526/48CB0F29

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/48CB0F29.svg?ark=w1%2F20260526%2F48CB0F29)](https://nobleid.org/work/w1/20260526/48CB0F29)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.

Identifier:nobleid.org/w1/20260526/48CB0F29

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/48CB0F29.svg?ark=w1%2F20260526%2F48CB0F29)](https://nobleid.org/work/w1/20260526/48CB0F29)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work